Artiva Biotherapeutics, Inc.
ARTVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Artiva Biotherapeutics, Inc. (ARTV) is listed under Biotechnology. The $547.1M market capitalization puts ARTV squarely in small-cap range for its industry. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Market Cap
$547.1M
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
-4.29
EPS (TTM)
$-3.24
EPS (Fwd)
$-2.61
ROE
-36.6%
ROA
-22.3%
Cash
$349.4M
Total Debt
$9.8M
Free CF
-$44.4M
52W Change
302.5%
Annual Financials
Cash vs Debt
Where ARTV stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, ARTV finished 42.40% above its 150-day moving average ($8.09) and 63.40% above its 200-day moving average ($7.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARTV overbought or oversold?
At the August 25, 2026 close, ARTV's RSI(14) was 55.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Artiva Biotherapeutics, Inc. holds $349.4M in cash against $9.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$44.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -36.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.9M (2022) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, ARTV tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ARTV has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ARTV.